title: Ocular distribution of the chimeric protein IL2-PE40.
abstract: A construct of IL-2 and pseudomonas exotoxin (PE40) has been genetically engineered. An aliquot of 100 microliter of the chimeric protein, radiolabelled with I125, was administered to healthy rats by various routes. At different intervals, ocular and non ocular tissues were removed and the levels of the radiolabelled chimeric protein IL-2-PE40 measured. Systemic administration of IL2-PE40 either intravenously (IV) or intraperitoneally (IP) leads to high levels of the drug in the blood, liver and spleen. Little or no radioactivity is observed within the ocular tissues using this route. On the other hand, local administration of the drug either as subtenon injection or as eye drops resulted in a very high concentration of the drug within the conjunctiva, cornea and sclera, with little radioactivity detected systemically. Subtenon injection induced a significant drug level within the optic nerve. With the drops, the chimeric protein was also detected, in low levels, intraocularly.
authors.affiliation: Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel.
authors.forename: D
authors.initials: D
authors.lastname: BenEzra
authors.forename: G
authors.initials: G
authors.lastname: Maftzir
authors.forename: E
authors.initials: E
authors.lastname: Hochberg
authors.forename: I
authors.initials: I
authors.lastname: Anteby
authors.forename: H
authors.initials: H
authors.lastname: Lorberboum-Galski
mesh_terms: D036002:ADP Ribose Transferases; D000818:Animals; D001427:Bacterial Toxins / Q000008:administration & dosage / Q000493:pharmacokinetics; D004333:Drug Administration Routes; D005098:Exotoxins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005123:Eye / Q000378:metabolism*; D000922:Immunotoxins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000493:pharmacokinetics*; D009883:Ophthalmic Solutions; D009915:Orbit / Q000187:drug effects; D011550:Pseudomonas aeruginosa; D051381:Rats; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
chemical_list: D036002:ADP Ribose Transferases; D001427:Bacterial Toxins; D005098:Exotoxins; D000922:Immunotoxins; D007376:Interleukin-2; D009883:Ophthalmic Solutions; D011993:Recombinant Fusion Proteins; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A